“Forget due to malpractice”. — Adrian Hernandez, MD, of the Duke Clinical Research Institute in Durham, North Carolina, commenting on a Med Page today research report featuring Texas Stella Immanuel, MD, the nation’s leading hydroxychloroquine and ivermectin prescriber for the past 2 years.
“We have a serious disease, we have a good vaccine… our collective thirst for additional data knows no bounds.” — David Kim, MD, of the Department of Health and Human Services, speaking at a meeting of the FDA advisory committee that recommended approval of GSK’s respiratory syncytial virus (RSV) vaccine in adults 60 years and older.
“It is not recommended to start vitamin D supplements to reduce the risk of dementia.” — Claire Sexton, DPhil, of the Alzheimer’s Association, discussing a study that suggested vitamin D supplementation was associated with a lower risk of dementia.
“Insanity is doing the same thing over and over again and expecting a different result.” — Mario Gaudino, MD, PhD, MSCE, of Weill Cornell Medicine in New York City, on the lack of improvement being made regarding the disproportionately increased mortality risk women face after coronary artery bypass grafting .
“Ideally, [the system] it should be more transparent about how brokers and agents earn options now.” — Gretchen Jacobson, vice president of the Commonwealth Fund’s Medicare program, speaking about agents and brokers directing clients to a Medicare Advantage plan.
“Because we don’t have those ICD codes within our eHealth system, those rare disease patients become invisible.” — Joni Rutter, PhD, director of the NIH National Center for Advancing Translational Sciences, noting that many rare diseases do not have an ICD code.
“I can tell you that many times within the Medicaid program, I have had a very difficult time getting authorization for biologics, and reauthorization is an even bigger problem.” — Anne Maitland, MD, PhD, of the Icahn School of Medicine at Mount Sinai in New York City, commenting on the barriers asthma patients face in obtaining a biologic prescription.
“It’s important for primary care providers to know that many of their patients with type 2 diabetes may qualify for these medications.” — Shichao Tang, PhD, of CDC’s Division of Diabetes Translation in Atlanta, after finding that less than 10% of eligible US patients with type 2 diabetes used a GLP-1 receptor agonist or an SGLT2 inhibitor in recent years.
“We’ve seen an increase in patients in their 30s and 40s with left-sided colon and rectal cancer.” — Michael Shusterman, MD, of the NYU Langone Perlmutter Cancer Center in New York City, speaking about research showing that colorectal cancer diagnoses have nearly doubled in younger people since 1995.
